UK’s Schroders pops 28% on Nuveen takeover that’s set to create asset management giant

UK’s Schroders pops 28% on Nuveen takeover that’s set to create asset management giant


Schroders soared to the top of the Stoxx 600 on Thursday, hitting a 52-week high, after U.S. fund management giant Nuveen said it would buy the U.K.’s largest standalone asset management.

The deal, sized at £9.9 billion ($13.5 billion), will create one of the world’s biggest asset management groups.

Nuveen — the investment management arm of the Teachers Insurance and Annuity Association of America (TIAA), a pensions and insurance group — will acquire Schroders for up to 612 pence per share.

The deal will create a global fund management behemoth with almost $2.5 trillion in assets under management, including $414 billion in combined private markets assets.

Shares in London-listed Schroders were up over 28% in morning trade following the announcement.

Stock Chart IconStock chart icon

hide content

Schroders PLC.

Under the agreement, the Schroders brand will be maintained, with the company remaining headquartered in London. Established in 1804, Schroders currently manages about £824 billion in assets, almost two-thirds of which are in the EMEA region.

Nuveen manages about $1.4 trillion in assets, 94% of which are in the Americas.

The transaction will deliver “an attractive premium in cash” to shareholders, Elizabeth Corley, chair of Schroders, said in a statement.

Group CEO Richard Oldfield added that the deal will “significantly accelerate our growth plans to create a leading public-to-private platform with enhanced geographic reach and a strengthened balance sheet.”

“This transaction is about unlocking new growth opportunities for wealth and institutional investors around the world by giving our leading, differentiated public-to-private platform a broader global presence,” said Nuveen CEO William Huffman.

End of an era

The takeover signals the end of the Schroders family’s control over the 220-year-old business — with the billionaire British-German banking dynasty having held a 44% stake — and comes amid a sharp turnaround in fortunes for the company, according to Panmure Liberum.

“Schroders was a mess,” Rae Maile, analyst at Panmure Liberum, said in a note, highlighting rising costs and disclosure shortcomings.

Schroders reported its second-half earnings on Thursday, which saw adjusted operating profits surge 25% in 2025 to £756.6 million, beating its £745 million guidance and Panmure’s earlier £674 million forecast, while AUM increased by 6%.

“In just 15 months, this new management team had set out a plan to reinvigorate the business — it had cut costs, shed tangential businesses and re-established its links with its home equity market. To have achieved quite so much, quite so quickly is staggering, but still the market was not reflecting that in either estimates or rating,” Maile added.



Source

Google joins Microsoft in telling users Anthropic is still available outside defense projects
World

Google joins Microsoft in telling users Anthropic is still available outside defense projects

Google CEO Sundar Pichai gestures to the crowd during Google’s annual I/O developers conference in Mountain View, California, on May 20, 2025. David Paul Morris | Bloomberg | Getty Images Google said it will continue offering Anthropic’s artificial intelligence technology for clients, excluding for defense work, a day after Microsoft issued a similar statement to […]

Read More
Market turmoil is hitting most traditional safe havens. UBS says this is the place to hide
World

Market turmoil is hitting most traditional safe havens. UBS says this is the place to hide

The U.S. and Israel are showing signs of escalating their war against Iran – a move that could batter a variety of assets, even traditional safe havens. To protect their portfolios, investors can snap up stocks from an oft-shorted sector: pharmaceuticals, UBS analysts say. Since the first strikes last Saturday, the Iran War has roiled […]

Read More
Zealand’s stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics’
World

Zealand’s stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics’

Wegovy is produced by pharmaceutical company Novo Nordisk and has been approved for specifically for chronic weight management in adults and adolescents. (Photo by Steve Christo – Corbis/Corbis via Getty Images) Steve Christo – Corbis | Corbis News | Getty Images The chief executive of drugmaker Zealand Pharma sought to calm investors about the latest […]

Read More